Healthcare Industry News:  female sexual dysfunction 


 News Release - August 15, 2014

Innovus Pharma and Consortia Health Initiate a Nationwide Marketing and Sales Campaign to U.S. Gynecologists for Zestra(R), Clinically Proven for the Enhancement of Female Arousal Desire and Satisfaction

SAN DIEGO, Aug. 15, 2014 -- (Healthcare Sales & Marketing Network) -- Innovus Pharmaceuticals, Inc., ("Innovus Pharma" or the "Company) (INNV) a leader in over-the-counter ("OTC") and consumer care products for men and women's sexual dysfunction and health products announced today that its U.S. sales and marketing partner, Consortia Health, began recently the detailing of its Zestra(R) product clinically proven to enhance arousal, desire and satisfaction in women to gynecologists in 13 states. Consortia's 25 member sales force is composed of sales representatives and nurse practitioners. The sales force currently covers over 50% of the US population in the following U.S. states: Pennsylvania, Michigan, Nevada, Texas, Florida, Louisiana, Georgia, New York, New Jersey, Colorado, Washington, Utah, California, North Carolina and Arizona.

The Company's nationwide marketing and direct sales campaign to gynecologists and therapists in the U.S. includes the following efforts:

  • Direct detailing of Zestra(R) to gynecologists with a commercial sales force;
  • Store specific sampling and referral program to gynecologists within 30 miles of retail stores that currently carry Zestra(R) in the US; and
  • Print Advertising for Zestra(R) in industry specific magazines including OB/GYN and Nurse Practitioners.

    "We are excited to announce the launch of our first nationwide sales and marketing effort," said Dr. Bassam Damaj, President and CEO of Innovus. "Through other products Consortia markets, they have established relationships within the medical arena, specifically with gynecologists."

    "We believe that the solid clinical trials supporting the product make Zestra(R) an ideal product to be detailed directly to gynecologists and therapists," Dr. Damaj added. "This is a large market with an unmet medical need for products, which cater specifically to over 20 million women suffering sexual arousal and desire disorders according to the Harris Report in the Interactive Women's Sexual Health Survey published in 2009 and we believe that the discreet environment of a physician's office will make our potential customers feel more comfortable purchasing our product. Additionally, there are currently no approved prescription products in the U.S. for women's sexual arousal and desire disorders. We anticipate the positive effects of their marketing programs to lead to a sizeable uptick in the sales of Zestra in 2015 and beyond."

    "We are excited about the opportunity to detail Zestra(R) in the states that our sales force currently covers," said Jeff Oliva President & CEO of Consortia Health. "As our team of highly specialized registered nurses assist physicians in diagnosing and treating pelvic floor and associated dysfunctions, we are humbled by the unmet need for our services and products like Zestra(R). By focusing discreetly, one patient at a time, we are in a unique position to help Consortia Health physician customers choose and employ innovative solutions to solve real life issues."

    "Zestra(R) is a strong clinically proven product in two U.S. double blind placebo controlled trials in 276 women to enhance arousal and desire and satisfaction. It is a perfect fit to our sales force to carry and detail to the gynecologists that we visit on daily basis," continued Mr. Oliva.

    "Our goal is to ensure that all of the ~45,000 gynecologists and therapists know about Zestra(R) and have clinical use experience with their patients and increase the product market share," stated Dr. Damaj.

    Zestra(R) is the only OTC natural product clinically proven in two U.S. double-blind, placebo controlled trials in 276 women to increase arousal, desire and satisfaction. Zestra(R) is commercialized and available in stores nationwide in the U.S. and Canada and has sold millions of units since its launch in 2007.

    About Innovus Pharmaceuticals, Inc.

    Headquartered in San Diego, Innovus Pharma is an emerging leader in the OTC male and female sexual dysfunction products. The Company generates revenues from its lead products Zestra(R) for female arousal, and EjectDelay(TM) for premature ejaculation, and has a total of four marketed products in this space including Sensum+(TM) (for sales outside the U.S. only) and Zestra Glide(R).

    For more information, go to

    About Consortia Health

    As a comprehensive program or independently, our services enhance your existing patient services for patients with pelvic floor disorders. Consortia Health is committed to supporting healthcare professionals with identification, diagnosis and treatment of pelvic floor disorders. With an experienced staff and leadership team that has assisted thousands of patients and their physicians in more than thirty states and four countries. Our mission is simple: improving patient lives by making medical center quality pelvic floor services available to any medical office. Our leadership team has diverse healthcare experience with clinics, hospitals, laboratories, medical research and Accountable Care Organizations (ACOs).

    For more information, go to


    Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, receiving patent protection for any of its products, receiving approval or to be compliant with the requirements of any relevant regulatory authority relating to such products such as Zestra(R), to successfully commercialize such products, and to achieve its other development, commercialization, financial and staffing objectives. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company.

    Source: Innovus Pharmaceuticals

    Issuer of this News Release is solely responsible for its content.
    Please address inquiries directly to the issuing company.

  • FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
    FindReps - available on the Apple App Store for iPhone and iPad.